<div>
  <ul>
    <li>
      <p>
        Genetic testing startup Epic Sciences has announced Medicare coverage of its 56-gene circulating tumor DNA (ctDNA) panel for genomic profiling of metastatic breast cancer by the MolDX program.
      </p>
    </li>
    <li>
      <p>
        The 56-gene ctDNA panel is a non-invasive test that delivers metastatic breast cancer profiling when a tissue biopsy result is not available. The key features of this test include its sensitivity, specificity, accuracy, and precision in the detection of circulating tumor cells, assessment of HER2 protein expression, and assessment of ER protein expression.
      </p>
    </li>
    <li>
      <p>
        Given that the ctDNA panel is part of Epic&rsquo;s DefineMBC blood biopsy test, it is also working on submitting additional evidence to establish Medicare coverage on the entirety of its DefineMBC blood biopsy tests so that the full benefit of its analysis can be available to patients with metastatic breast cancer.&nbsp;
      </p>
    </li>
  </ul>
  <p>
  </p>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.businesswire.com/news/home/20230419005773/en/Epic-Sciences-Announces-Medicare-Coverage-for-Breast-Cancer-Focused-ctDNA-Gene-Panel">
      Company Press Release
    </a>
  </p>
  <p>
    <a href="https://www.biospace.com/article/releases/epic-sciences-announces-medicare-coverage-for-breast-cancer-focused-ctdna-gene-panel/?keywords=precision">
      BioSpace
    </a>
  </p>
  <p>
  </p>
</div>


All Updates

Epic Sciences receives Medicare coverage for breast cancer-focused ctDNA gene panel

Epic Sciences raises USD 24 million in Series G